Sorrento Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 31.91 | -100% | 0 | 0% |
| P/S |
|
6.64 | 3.27 | 103.31% |
|
|
| P/BV |
|
-19.26 | 3.37 | -672.21% |
|
|
| P/FCF |
|
0 | 160.71 | -100% |
|
|
| Ev/Ebitda |
|
-0.7948 | 10.03 | -107.92% |
|
|
| Ev/S |
|
6.83 | 1.91 | 258.22% |
|
|
| Ev/FCF |
|
-1.4 | 20.45 | -106.82% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-859.22 | 24.26 | -3642.24% | -845.85 | +1.58% |
| ROE |
|
-1904.94 | 13.23 | -14495.52% |
|
|
| ROA |
|
-98.12 | 6.16 | -1693.65% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-912.1 | 12.56 | -7362.25% |
|
|
| ROCE |
|
0 | 14.33 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 6.16 | -100% | -0.1606 | -100% |
| Nеt Debt/Ebitda |
|
-0.0219 | -5.78 | -99.62% |
|
|
| Debt/Ratio |
|
0 | 0.2073 | -100% |
|
|
| Debt/Equity |
|
0 | 3.39 | -100% |
|
|
| Debt/Net Income |
|
0 | 14.94 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.25 | -100% | ||
| DSI |
|
0 | 0.7878 | -100% |
|
|
| Average dividend growth |
|
0 | -97.92 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.83 | -100% |
|
|
| Average percentage for payments |
|
0 | 246.75 | -100% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
100.12 | 140.59 | -28.79% | ||
| Growth impulse Ebitda in 5 years |
|
72.83 | 106.87 | -31.85% | ||
| Growth impulse Net Income in 5 years |
|
96.11 | 123.16 | -21.96% | ||
| Growth impulse FCF in 5 years |
|
66.76 | 93.7 | -28.75% | ||
| Growth impulse EPS in 5 years |
|
-75.29 | 239.27 | -131.47% |
IP Score
4.18/10
